Six months after Genmab and AbbVie disclosed topline results from the Phase 3 EPCORE DLBCL-1 trial, the companies felt compelled to issue a public clarification on something that should have been unambiguous from the start: overall survival was the sole U.S. primary endpoint, and the trial did not meet it. That a formal press release is necessary to establish this point suggests the original January announcement left room for enough interpretive flexibility that stakeholders needed the record corrected explicitly.
The trial enrolled adults with relapsed or refractory DLBCL who were ineligible for autologous stem cell transplantation, comparing subcutaneous epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy, either R-GemOx or bendamustine-rituximab. The design carried a notable structural wrinkle: primary endpoints differed by region. That regional endpoint divergence, while not unusual in global oncology trials, creates exactly the kind of interpretive ambiguity that apparently persisted through the January topline readout and the June presentation at EHA 2026. A trial can simultaneously meet a primary endpoint in one region and fail in another, and communicating that cleanly to investors, clinicians, and regulators requires precision that the initial disclosures apparently did not deliver.
The regulatory stakes here are real. Epcoritamab already carries FDA accelerated approval for R/R DLBCL after two or more prior lines, granted on the basis of earlier single-arm data. A Phase 3 OS miss does not automatically revoke accelerated approval, but it substantially complicates the path to full conversion and raises questions about monotherapy positioning in a setting where CAR-T therapies are established options for transplant-eligible patients and chemoimmunotherapy remains the practical standard for the transplant-ineligible population this trial targeted. The companies now plan peer-reviewed publication of full results, which will matter for how oncologists interpret the survival curves in clinical context.
The more consequential near-term data point sits elsewhere in the epcoritamab program: topline results from EPCORE DLBCL-2, evaluating epcoritamab combined with R-CHOP in newly diagnosed DLBCL, are expected before year-end. Whether that combination can deliver on OS in a front-line setting will define the drug’s commercial trajectory far more than any clarification memo about a failed monotherapy trial in late-line, transplant-ineligible patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
